Barinthus Biotherapeutics plc.
BRNS$26M
Micro CapNASDAQPharmaceutical PreparationsVaccines🇺🇸North AmericaGERMANTOWN105 employees
Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people.
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
BRNS News
Catalyst Timeline
0 upcoming, 3 past
No catalysts found.
Drug Pipeline
MVA-HBV
Chronic Hepatitis B
ChAdOx1-HBV
Hepatitis B
ChAdOx1-HPV
HPV Infection
MVA-NP+M1
Influenza
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MVA-HBV | Phase 2 | Chronic Hepatitis B | - | - |
ChAdOx1-HBV | Phase 2 | Hepatitis B | - | - |
ChAdOx1-HPV | Phase 2 | HPV Infection | - | - |
MVA-NP+M1 | Phase 2 | Influenza | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply